Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraro, Emanuela, Drago, Joshua Z., Modi, Shanu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356386/
https://www.ncbi.nlm.nih.gov/pubmed/34380530
http://dx.doi.org/10.1186/s13058-021-01459-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356386/
https://www.ncbi.nlm.nih.gov/pubmed/34380530
http://dx.doi.org/10.1186/s13058-021-01459-y

Ejemplares similares